About Par Formulations Private Limited
Data last updated:
Par Formulations Private Limited is a private limited company based in Chennai, Tamil Nadu, India, a subsidiary of Par Pharmaceuticals Inc.. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 22 September 1982 and has been in existence for over 44 years.
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN U33111TN1982PTC009602. Its GSTIN is 33AAACC2463N1ZP (Tamil Nadu). The company holds 3 GST registrations, all of them active.
The company has an authorised share capital of ₹2.2 Cr and a paid-up capital of ₹2.14 Cr. It was formerly known as Novel Therapeutics Private Limited and Edict Pharmaceuticals Private Limited. It is led by directors Chitti Babu Sampath Kumar (Whole-Time Director) and Anand Amrit Raj.
Its last annual general meeting (AGM) was held on 26 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 9/215 Pudupakkam – Vandalur Main Road Pudupakkam Kelambakkam, Chennai, Tamil Nadu, India – 603103.
As per the financials filed for FY 2025, the company reported a revenue of ₹1,462.09 Cr, a growth of 5% compared to the previous year. For the same year it recorded a net profit of ₹28.41 Cr (net margin 1.9%) and EBITDA of ₹252.79 Cr (EBITDA margin 17.3%). Revenue has grown at a compounded annual rate (CAGR) of 13% over three years and 19% over five years.
The company has about 1,304 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.
The company is associated with 2 brands: Endo International and Par Pharmaceutical Companies. As per MCA filings, the company has open charges of ₹17.13 Lakh and satisfied charges of ₹62.37 Cr on record. Court records list 18 cases involving the company, including 16 filed by the company and 2 filed against it; 7 cases are pending. The company has 16 deals on record (8 funding rounds, 7 secondary share transfers, 1 convertible or debt financing), with disclosed funding of ₹187.08 Cr; the latest was in March 2023. Its 4 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 1 smaller; the largest is Indoco Remedies Limited with revenue of ₹1,670.37 Cr. The company has 7 MSME Form 1 returns on record between 2019 and 2024, listing 76 overdue payments to 26 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website parpharm.com.
Company details
Name history
Par Formulations has undergone 4 name changes throughout its history. The current legal name is Par Formulations Private Limited.
| Company Name | Status |
|---|---|
| Par Formulations Private Limited | Current |
| Novel Therapeutics Private Limited | Previous |
| Edict Pharmaceuticals Private Limited | Previous |
| Chk Electroniks Private Limited | Previous |
| Ch Krishnan And Associates Private Limited | Previous |
Contact details
Par Formulations Private Limited's registered office is in Chennai, Tamil Nadu. Its website is parpharm.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address9/215 Pudupakkam – Vandalur Main Road Pudupakkam Kelambakkam, Chennai, Tamil Nadu, India – 603103
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Par Formulations Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Par Formulations operates two associated brands: Endo International and Par Pharmaceutical Companies. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Global pharmaceutical company manufacturing branded, generic formulations, and OTC medicines | endo.com | |
| Pharmaceutical products are developed for endocrinology, orthopedics, and urology. | parpharm.com |
Business activity
The main business activities of Par Formulations are manufacturing and professional, scientific and technical. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and scientific research and development. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| M | Professional, Scientific and Technical | M5 | Scientific research and development |
To see the full business activity and turnover split of Par Formulations Private Limited, buy the company report.
Financials of Par Formulations Private Limited
FY 2024 filings availablePar Formulations Private Limited reported revenue of ₹1,462.09 Cr (up 5% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 19% over five years, including 5% growth in the latest year. EBITDA fell 2% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹252.79 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹28.41 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 17.3% | ||||
| Net Profit Margin | 1.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Par Formulations Private Limited, buy the company report.
Board of directors of Par Formulations Private Limited
Par Formulations has 2 current directors and 25 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Chitti Babu Sampath Kumar | Whole-Time Director | 28 Jun 2017 | 9 Years 4 Months | Current |
| Anand Amrit Raj | Director | 27 May 2022 | 4 Years 5 Months | Current |
Peer comparison
Par Formulations Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Indoco Remedies Limited | ₹1,670.37 Cr (FY 2025) | -9.0% | Mumbai, Maharashtra, India | |||
| Annora Pharma Private Limited | ₹1,493.96 Cr (FY 2025) | 22.0% | Gummadidala Mandal, Telangana, India | |||
| Synthimed Labs Private Limited | ₹1,478.44 Cr (FY 2025) | 25706.0% | Chandigarh, India | |||
| Par Formulations Private Limitedthis company | ₹1,462.09 Cr (FY 2025) | ₹28.41 Cr | 1.9% | 5.0% | 1,304 | Chennai, Tamil Nadu, India |
| Sentiss Pharma Private Limited | ₹1,262.74 Cr (FY 2025) | 43.0% | New Delhi, Delhi, India |
To see the full peer comparison of Par Formulations Private Limited, buy the company report.
Auditor
Par Formulations Private Limited is audited by Price Waterhouse & Co Chartered Accountants LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Price Waterhouse & Co Chartered Accountants LLP | FY 2023 | 304026E/E-300009 |
Shareholding
The shareholding of Par Formulations Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Par Formulations Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 08 Aug 2022 | 100611324 | Others | ₹12.13 Lakh | Open | |
| 08 Aug 2022 | 100611327 | Others | ₹5 Lakh | Open | |
| 08 Aug 2022 | 100611617 | Others | ₹27.06 Cr | Satisfied | |
| 04 Feb 2010 | 10206083 | State Bank of India | ₹18 Cr | Satisfied | |
| 06 Mar 2008 | 10109950 | State Bank of India | ₹15 Cr | Satisfied |
To see the full charge records of Par Formulations Private Limited, buy the company report.
Total charge records: 10 View all charges
Deals & funding
Par Formulations Private Limited has 16 deals on record (8 funding rounds, 7 secondary share transfers, 1 convertible or debt financing), with disclosed funding of ₹187.08 Cr; the latest was in March 2023.
Deals on record (5 of 16)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2023 | Secondary share transfer | Undisclosed | Buyer: Endo India Holdings LLC Seller: Par Pharmaceuticals Inc, Par Llc |
| Feb 2012 | Secondary share transfer | Undisclosed | Buyer: Par Llc, Par Pharmaceuticals Inc Seller: Clan Laboratories Private Limited , Thretha Investments and Portfolio Services Private Limited , 2 individuals |
| Oct 2009 | Secondary share transfer | Undisclosed | Buyer: Clan Laboratories Private Limited Seller: Ordain Health Care Private Limited |
| Aug 2009 | Funding round | ₹79.3 Lakh | Investors: Thretha Investments and Portfolio Services Private Limited , an individual |
| Mar 2009 | Secondary share transfer | Undisclosed | Buyer: Clan Laboratories Private Limited Seller: an individual |
To see the full deal history of Par Formulations Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Par Formulations Private Limited has 18 court cases on record: 16 filed by Par Formulations, 2 filed against it. 7 cases are pending and 11 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 10 | 1 | 3 |
| NCLAT | 5 | 0 | 4 |
| District courts | 3 | 1 | 0 |
Cases on record (5 of 18)
| Court | Type of case | Party | Status |
|---|---|---|---|
| NCLAT, NCLAT New Delhi | Interim or miscellaneous application | Filed by the company against Print House (India) Private Limited and 2 others | Pending |
| NCLAT, Court II | Tribunal matter | Filed by the company against Print House (India) Private Limited and 2 others | Disposed |
| Madras High Court | Interim or miscellaneous application | Filed against the company by The Additional Commissioner of CGST and Central Excise | Pending |
| High Court, TAMIL NADU | Writ petition | Filed by the company against The Additional Commissioner of CGST and Central Excise and 1 other | Pending |
| High Court, TAMIL NADU | Interim or miscellaneous application | Filed by the company against The Additional Commissioner of CGST and Central Excise and 1 other | Pending |
To see the full case history of Par Formulations Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Par Formulations Private Limited has 7 MSME Form 1 returns on record between 2019 and 2024, listing 76 overdue payments to 26 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 26)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Anant Pharmaceuticals Private Limited | |||
| Human Lifescience | |||
| Chromatography World | |||
| Chempura Enterprises |
To see the full MSME payment records of Par Formulations Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Par Formulations has 2 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Par Active Technologies Private Limited | U24232TN2013PTC093471 | |
| Par Biosciences Private Limited | U24233TN2012PTC086326 |
To see the full group structure of Par Formulations Private Limited, buy the company report.
Employees & EPFO
Par Formulations Private Limited has a workforce of 1,304 employees on its EPFO records as of Apr 05, 2024, across 1 active EPFO establishment.
GST
Par Formulations has 3 GST registrations: 3 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 33AAACC2463N1ZP | Tamil Nadu | Active | 01 Jul 2017 |
| 27AAACC2463N1ZI | Maharashtra | Active | 15 Aug 2017 |
| 23AAACC2463N1ZQ | Madhya Pradesh | Active | 13 Apr 2019 |
To see the full GST registrations and return filing status of Par Formulations Private Limited, buy the company report.
Recent activity
Par Formulations Private Limited has 26 board changes on record since 2007: 4 appointments and 22 cessations. The latest: Nazneen Nasir Khan was appointed as Company Secretary on 16 Jul 2025.
38 earlier events are in the company report.
Frequently asked questions
Par Formulations is an active private limited company based in Chennai, Tamil Nadu, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 22 September 1982 (44+ years old) and is registered under CIN U33111TN1982PTC009602.
Par Formulations has 2 current directors:
- Chitti Babu Sampath Kumar - Whole-Time Director
- Anand Amrit Raj - Director
The latest financial statements of Par Formulations on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 26 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Par Formulations is 33AAACC2463N1ZP, registered in Tamil Nadu. The company has 3 GST registrations in all, of which 3 are active. Other active GSTINs include 27AAACC2463N1ZI (Maharashtra), 23AAACC2463N1ZQ (Madhya Pradesh).
The CIN (Corporate Identification Number) of Par Formulations is U33111TN1982PTC009602. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Par Formulations has 18 court cases on record: 16 filed by the company and 2 filed against it. 7 are pending. Most are in the high courts.
Par Formulations was incorporated on 22 September 1982, making it 44+ years old. It is registered with the Registrar of Companies, Chennai.
Par Formulations has 16 deals on record (8 funding rounds, 7 secondary share transfers, 1 convertible or debt financing), with disclosed funding of ₹187.08 Cr; the latest was in March 2023.
The peers of Par Formulations by revenue are Indoco Remedies Limited, Annora Pharma Private Limited, Synthimed Labs Private Limited, Sentiss Pharma Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Nazneen Nasir Khan was appointed as Company Secretary on 16 Jul 2025. Anand Amrit Raj ceased to be Additional Director on 30 Sep 2022. Anand Amrit Raj was appointed as Director on 27 May 2022. Par Formulations has 26 board changes on record in total.
Par Formulations has 7 MSME Form 1 returns on record between 2019 and 2024, listing 76 overdue payments to 26 micro and small suppliers. The latest return was filed on 30 Apr 2024.
Par Formulations can be reached through the website parpharm.com. Its registered office is in Chennai, Tamil Nadu, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
